Prognostic Value of MRI ‐Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST , LI ‐ RADS TRA Version 2017, and LI ‐ RADS Radiation TRA Version 2024
Journal of Magnetic Resonance Imaging · 2026-08 · 64 (2) · 454-465
DOI: 10.1002/jmri.70334 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Magnetic Resonance Imaging, online erschienen am 17.04.2026. Verfasst von Fan Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center f…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Radiosurgery, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
Accurate imaging assessment of hepatocellular carcinoma (HCC) after stereotactic body radiotherapy (SBRT) remains challenging. Although LI‐RADS CT/MRI Radiation Treatment Response Assessment (TRA v2024) was developed for this purpose, its prognostic value for survival stratification after SBRT remains to be validated.
Purpose
To compare the prognostic performance of mid‐term (3–6 months) and late‐term (9–12 months) MRI‐based treatment response assessed using modified RECIST (mRECIST), LI‐RADS TRA v2017, and LI‐RADS Radiation TRA v2024 in patients with HCC. Study Type Retrospective cohort study. Population 125 patients with HCC underwent SBRT (111 males; mean age, 56.4 ± 10.8 years). Field Strength/Sequence 3.0 T; axial fat‐suppressed fast spin‐echo T2‐weighted imaging, diffusion‐weighted imaging, pre‐contrast gradient recalled echo T1‐weighted imaging, and contrast‐enhanced late arterial phase, portal venous phase, and delayed/transitional phase. Assessment Tumor response was independently evaluated by three radiologists using three treatment assessment methods. Ancillary features (AFs) were additionally recorded to assess their incremental prognostic value. Overall survival (OS) and progression‐free survival (PFS) were analyzed according to response categories. Statistical Tests Kolmogorov–Smirnov test, Intraclass correlation coefficients, Cohen's κ, Variance inflation factor analysis, Kaplan–Meier method, Log‐rank tests with Bonferroni correction, Univariate and multivariable Cox regression analyses. Statistical significance was defined as p < 0.05.
Results
At mid‐term follow‐up, LI‐RADS Radiation TRA v2024 showed greater discrimination for PFS than mRECIST and LI‐RADS TRA v2017, with no OS difference ( p > 0.999). Across all three criteria, late‐term response assessment yielded better prognostic stratification for PFS and OS than did mid‐term evaluation. At the late‐term follow‐up, LI‐RADS Radiation TRA v2024 was strongly associated with OS (HR = 15.80, 95% CI: 3.34–75.00) and PFS (HR = 6.31, 95% CI: 2.68–14.90). Adding AFs provided no further prognostic improvement. Data Conclusion LI‐RADS Radiation TRA v2024 demonstrates strong prognostic stratification after SBRT, particularly at late‐term MRI evaluation. Evidence Level 3. Technical Efficacy Stage 2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. Chin…
- Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Chuanmiao Xie
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Foundation of Guangdong Province
Zitieren
APA
Zhou, F., Ma, L., Wei, J., Liao, S., Zheng, Y., Geng, Z., & Xie, C. (2026). Prognostic Value of MRI ‐Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST , LI ‐ RADS TRA Version 2017, and LI ‐ RADS Radiation TRA Version 2024. Journal of Magnetic Resonance Imaging, 64(2), 454-465. https://doi.org/10.1002/jmri.70334
Vancouver
Zhou F, Ma L, Wei J, Liao S, Zheng Y, Geng Z, et al. Prognostic Value of MRI ‐Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST , LI ‐ RADS TRA Version 2017, and LI ‐ RADS Radiation TRA Version 2024. Journal of Magnetic Resonance Imaging. 2026;64(2):454-465. doi:10.1002/jmri.70334
BibTeX
@article{Zhou2026,
author = {Zhou, Fan and Ma, Lidi and Wei, Jiaqi and Liao, Shuting and Zheng, Yuquan and Geng, Zhijun and Xie, Chuanmiao},
title = {Prognostic Value of MRI ‐Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST , LI ‐ RADS TRA Version 2017, and LI ‐ RADS Radiation TRA Version 2024},
journal = {Journal of Magnetic Resonance Imaging},
year = {2026},
volume = {64},
number = {2},
pages = {454--465},
doi = {10.1002/jmri.70334}
}
EUVIMED